Stampacchia Otello 4
4 · Kronos Bio, Inc. · Filed Oct 16, 2020
Insider Transaction Report
Form 4
Kronos Bio, Inc.KRON
Stampacchia Otello
Director
Transactions
- Purchase
Common Stock
2020-10-14$19.00/sh+450,000$8,550,000→ 3,818,283 total(indirect: By Omega Fund V, LP) - Conversion
Series A Preferred Stock
2020-10-14−1,304,563→ 0 total(indirect: By Omega Fund V, LP)→ Common Stock (1,376,313 underlying) - Conversion
Common Stock
2020-10-14$16.15/sh+366,299$5,915,729→ 3,368,283 total(indirect: By Omega Fund V, LP) - Conversion
Common Stock
2020-10-14+1,606,220→ 1,625,671 total(indirect: By Omega Fund V, LP) - Conversion
Common Stock
2020-10-14+1,376,313→ 3,001,984 total(indirect: By Omega Fund V, LP) - Conversion
Series Seed Preferred Stock
2020-10-14−1,522,484→ 0 total(indirect: By Omega Fund V, LP)→ Common Stock (1,606,220 underlying) - Conversion
Convertible Promissory Note
2020-10-14→ 0 total(indirect: By Omega Fund V, LP)Exercise: $16.15Exp: 2022-02-20→ Common Stock (366,299 underlying)
Footnotes (3)
- [F1]Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
- [F2]The reporting person, Claudio Nessi and Anne-Mari Paster are the directors of Omega Fund V GP Manager, Ltd. ("Omega Manager"), which is the sole general partner of Omega V Fund GP, L.P. ("Omega GP"), which is the sole general partner of Omega Fund V, L.P. ("Omega L.P."). The reporting person may be deemed to share voting and dispositive power over the shares held by Omega L.P. The reporting person, together with Omega GP and Omega Manager, disclaims beneficial ownership of the shares held by Omega L.P. except to the extent of his pecuniary interest therein.
- [F3]The convertible promissory note automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering.